Genetics, Screening, and Risk-reducing Interventions for Breast Cancer

This publication has 47 references indexed in Scilit:

• Management of individuals with germline pathogenic/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)
  Genetics in Medicine, 2023
• The clinical application of polygenic risk scores: A points to consider statement of the American College of Medical Genetics and Genomics (ACMG)
  Genetics in Medicine, 2023
• Breast cancer screening in women with extremely dense breasts recommendations of the European Society of Breast Imaging (EUSOBI)
  European Radiology, 2022
• Breast Cancer Screening Strategies for Women With ATM, CHEK2, and PALB2 Pathogenic Variants
  JAMA Oncology, 2022
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
  JAMA, 2017
• Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review
  The American Journal of Surgery, 2016
• Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort
  Cancer, 2016
• Prevalence of BRCA1/2 mutations in sporadic breast/ovarian cancer patients and identification of a novel de novo BRCA1 mutation in a patient diagnosed with late onset breast and ovarian cancer: implications for genetic testing
  Breast Cancer Research and Treatment, 2011
• Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
  JAMA, 2006
• A breast cancer prediction model incorporating familial and personal risk factors
  Statistics in Medicine, 2004